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aBstraCt
To disclose a case of wet age-related macular degeneration (wet AMD) combined with branch retinal vein occlusion 
(BRVO). The prognosis and the treatment are discussed. A 77-year-old woman presented with wet AMD of the left 
eye. The patient was treated with intravitreal injection of ranibizumab of the left eye with improvement of visual 
acuity and resolution of intra-retinal and sub-retinal fluid. One year after the last injection the patient developed  
a BRVO of the same eye. A flame shaped haemorrhage was observed, and OCT examination showed cystic macular 
oedema. Fluorescein angiography showed that there was an active lesion of choroidal neovascularisation (CNV), 
areas of ischaemia, delayed filling and emptying of the affected vein, micro aneurisms, and telangiectatic changes. 
The co-existence of BRVO and active WET AMD was documented by fluorescein angiography. The co-existence of 
both diseases has not been described in the literature until today. This co-existence makes the prognosis worse and 
diminishes the patient’s visual acuity.
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introduCtion
It is common knowledge that macular degenera-
tion is diagnosed as either dry (non-neovascular) or 
wet (neovascular) [1]. The majority of patients pres-
ent with dry macular degeneration (DRY AMD). In 
about 10% of all patients diagnosed with macular 
degeneration, the disease progresses to wet type (wet 
AMD). Some of the risk factors for wet AMD are age 
[1, 2], smoking [3, 4], and genetic susceptibility [5]. 
Other risk factors are cardiovascular disease, hyper-
tension, female gender, white race [6], hypercho-
lesterolaemia, obesity, hyperopia [7], and family 
history. 
In order to observe and evaluate the progression 
of AMD (both dry and wet), retinoscopy with full 
pupil dilation is necessary. Optical Coherence To-
mography (OCT) offers a high-resolution, non-in-
vasive, optical cross-sectional method that utilises 
low-coherence interferometry [8]. OCT is a valua-
ble diagnostic tool that helps monitor and evaluate 
the progression of the disease with accuracy.
Although there is no current treatment for dry 
AMD, when it comes to wet AMD there are sever-
al options. Macular photocoagulation was studied 
in 1980s for limiting damage caused by choroidal 
neovascular lesions [9, 10]. Photodynamic therapy 
was also used in the late 1990s. The most up-to-
date treatment for wet AMD is probably anti-vas-
cular endothelial growth factor (anti-VEGF) injec-
tions. Substances such as ranibizumab, bevacizum-
ab, and aflibercept have been employed to reduce 
the proliferation of abnormal leaky blood vessels 
grown from the choroidal layer through Bruch’s 
membrane, into the retinal layers.
Branch retinal vein occlusion (BRVO) is a ve-
nous occlusion at any branch of the central retinal 
vein. It is classified according to the anatomical 
location as major or macular. Major BRVO refers 
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Figure 1. OCT image of the patient during a routine visit
to occlusion of a retinal vein that drains one of the 
quadrants. Macular BRVO refers to occlusion of 
a venule within the macula [11]. Some risk factors 
leading to BRVO are age, hypertension, hyperlipi-
daemia, ocular hypertension, and glaucoma [12, 13].
When treating BRVO, the aimed treatment 
is to prevent the complications that cause vision 
loss, such as macular oedema, macular ischaemia, 
and neovascularisation. BRVO can be treated with 
photocoagulation [14, 15], steroid treatment [16], 
and/or anti-VEGF injections [17–19].
Case report
A 77-year-old female came to the office on 
a scheduled appointment. The patient’s visual acu-
ity was 20/20 in the right eye and 20/400 in the 
left eye. She was already diagnosed with wet AMD 
in the left eye and had already received eight anti- 
-VEGF injections. 
On the left eye, a haemorrhage was observed 
with fundoscopy, which referred to BRVO. An 
OCT examination was performed which showed 
cystic macular oedema, sub-retinal fluid, and an 
area of hyper-reflectivity at the ISOS junction of the 
left eye (Fig. 1). 
From the fundus image, we suspected that the 
case of wet AMD was complicated by BRVO. 
A fluo rescein angiography was performed.
Blocked fluorescence was observed due to the 
retinal haemorrhages seen through all phases of the 
angiography. There was delayed filling and empty-
ing of the affected vein, dilated capillaries, micro- 
-aneurisms, and telangiectatic changes. Areas of 
capillary closure were presented on the upper left 
quadrant. Late staining and leakage from the af-
fected vein was observed. In the subfoveal area, 
there was staining due to old CNV lesions. In the 
inferotemporal area of the fovea, there was a spot of 
hyper-fluorescence, which corresponded to an area 
of active choroidal neovascularisation.
In Figure 2 and 3 the early and late times of the 
test are depicted. 
Fluorescein angiography proved the existence 
of an active choroidal neovascularisation combined 
with BRVO. We decided to treat the patient with 
a ranibizumab injection.
After the injection, the patient was prescribed ox-
ifloxacin four times daily for a week in order to avoid 
the risk of ocular infection. Three days after the in-
jection another OCT was performed, which showed 
improvement of both macular oedema (Fig. 4).
One month after the anti-VEGF injection, the 
patient came for a follow up. A measurement of Best 
Corrected Visual Acuity (BCVA) was performed as 
well as OCT imaging (Fig. 5). 
Unfortunately, visual acuity remained 20/400. 
OCT examination showed complete resolution of 
the cystoid macular oedema and sub-retinal fluid. 
Fundus examination showed resolution of the 
haemorrhages of the BRVO as well.
disCussion
Despite the fact that the patient responded very 
well to the treatment, visual acuity did not improve 
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Figure 4. OCT image of the patient 3 days after anti-VEGF injection
Figure 2. Early times of fluorescein angiography Figure 3. Late times of fluorescein angiography
at all. This was attributed to the fact that the big 
cystic spaces filled with fluid, even though they 
dried out with the anti-VEGF injection, caused per-
manent damage to the intra-retinal network. This 
damage contributed to poor visual acuity. 
To our knowledge there has not been any other 
report on the literature of wet AMD co-existing 
with BRVO. This was probably the most aggravat-
ing factor of the remaining poor visual acuity.
As referred in the literature, wet AMD and 
BRVO have several risk factors in common, such as 
hypertension and cardiovascular disease. In the re-
ported case, the patient was already diagnosed with 
hypertension and is now under treatment.
What should also be mentioned is that the pa-
tient is diabetic. That plays an important role in 
the quality of the patient’s blood vessels all over her 
body and, in this case, in the retina. Diabetes can 
contribute to BRVO, usually by causing high blood 
pressure [20]. Moreover, there are studies [21] link-
ing diabetes to severe wet AMD. 
Concluding, when combining diabetes and hy-
pertension (that may or may not have derived from 
diabetes), a possible explanation occurs for the co-ex-
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Figure 5. OCT image, one month after anti-VEGF injection
istence of BRVO and wet AMD. What should be 
noted is that patients who already know that they have 
hypertension and/or diabetes should check regularly 
with their ophthalmologist for a thorough exami-
nation that also includes OCT imaging. In this way 
there is a high possibility to control and prevent any 
pathological changes in the fundus from becoming 
permanent and to lead to irreversible loss of vision.
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